메뉴 건너뛰기




Volumn 17, Issue 7, 2015, Pages 510-526

An overview of current regulatory requirements for approval of biosimilar insulins

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; INSULIN DERIVATIVE;

EID: 84942300689     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2014.0362     Document Type: Review
Times cited : (32)

References (60)
  • 1
    • 85008260747 scopus 로고    scopus 로고
    • Terminology for biosimilars-A confusing minefield
    • Thorpe R, Wadhwa M: Terminology for biosimilars-a confusing minefield. GaBI J 2012;1:132-134.
    • (2012) GaBI J , vol.1 , pp. 132-134
    • Thorpe, R.1    Wadhwa, M.2
  • 2
    • 84871639510 scopus 로고    scopus 로고
    • Opportunities and challenges for biosimilars: What's on the horizon in the global insulin market?
    • Rotenstein LS, Ran N, Shivers JP, et al.: Opportunities and challenges for biosimilars: what's on the horizon in the global insulin market? Clin Diabetes 2012;30:138-150.
    • (2012) Clin Diabetes , vol.30 , pp. 138-150
    • Rotenstein, L.S.1    Ran, N.2    Shivers, J.P.3
  • 3
    • 84868017986 scopus 로고    scopus 로고
    • The emergence of biosimilar insulin preparations: A cause for concern?
    • Owens DR, Landgraf W, Schmidt A, et al.: The emergence of biosimilar insulin preparations: a cause for concern? Diabetes Technol Ther 2012;14:989-996.
    • (2012) Diabetes Technol Ther , vol.14 , pp. 989-996
    • Owens, D.R.1    Landgraf, W.2    Schmidt, A.3
  • 4
  • 5
    • 84881356882 scopus 로고    scopus 로고
    • Biosimilar insulins: Opportunities and challenges
    • Gough S: Biosimilar insulins: opportunities and challenges. Pract Diabetes 2013;30:146-148.
    • (2013) Pract Diabetes , vol.30 , pp. 146-148
    • Gough, S.1
  • 6
    • 78049362302 scopus 로고    scopus 로고
    • Expert Committee on Biological Standardization, Geneva, 19-23 October. (accessed January 27, 2014)
    • World Health Organization: Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Expert Committee on Biological Standardization, Geneva, 19-23 October 2009. www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf (accessed January 27, 2014).
    • (2009) Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)
  • 9
    • 84863435547 scopus 로고    scopus 로고
    • The advent of biosimilar therapies in rheumatology-"O brave new world."
    • Scheinberg MA, Kay J: The advent of biosimilar therapies in rheumatology-"O brave new world." Nat Rev Rheumatol 2012;8:430-436.
    • (2012) Nat Rev Rheumatol , vol.8 , pp. 430-436
    • Scheinberg, M.A.1    Kay, J.2
  • 10
    • 33644952525 scopus 로고    scopus 로고
    • (accessed August 13, 2014)
    • European Medicines Agency: EMA Guideline on Similar Biological Medicinal Products. 2005. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003517.pdf (accessed August 13, 2014).
    • (2005) EMA Guideline on Similar Biological Medicinal Products
  • 11
    • 33644952525 scopus 로고    scopus 로고
    • Draft. (accessed August 13, 2014)
    • European Medicines Agency: EMA Guideline on Similar Biological Medicinal Products. Draft. 2013. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/05/WC500142978.pdf (accessed August 13, 2014).
    • (2013) EMA Guideline on Similar Biological Medicinal Products
  • 17
    • 85082156098 scopus 로고    scopus 로고
    • Decreto por el que se Reforman y Adicionan Diversas Disposiciones del Reglamento de Insumos Para la Salud
    • (accessed August 13, 2014)
    • Official Journal of the Federation: Decreto por el que se Reforman y Adicionan Diversas Disposiciones del Reglamento de Insumos Para la Salud. 2011. http://dof.gob.mx/nota-detalle.php?codigo=5214882&fecha=19/10/2011 (accessed August 13, 2014).
    • (2011) Official Journal of the Federation
  • 18
    • 85082149634 scopus 로고    scopus 로고
    • Version 1.1. (accessed August 13, 2014)
    • Saudi Food & Drug Authority: Guidelines on Biosimilars. Version 1.1. 2010. http://old.sfda.gov.sa/NR/rdonlyres/CB28C6AF-79CD-4412-8801-35AEDEED0183/0/Guidelines onbiosimilars-v11.pdf (accessed August 13, 2014).
    • (2010) Guidelines on Biosimilars
  • 19
    • 85082158718 scopus 로고    scopus 로고
    • (accessed August 13, 2014)
    • Jordan Food & Drug Administration: Guidance for Registration of Biosimilars. 2013. www.jfda.jo/Download/News/239-530.pdf (accessed August 13, 2014).
    • (2013) Guidance for Registration of Biosimilars
  • 20
    • 85082156013 scopus 로고    scopus 로고
    • (accessed August 13, 2014)
    • Egyptian Ministry of Health, Central Administration for Pharmaceutical Affairs, General Registration Department, Department of Biological Products Registration: Draft Guideline for Registration of Biosimilar Products. 2012. www.eda.mohp.gov.eg/Download/Docs/Final%20biosimilar %20guideline.pdf (accessed August 13, 2014).
    • (2012) Draft Guideline for Registration of Biosimilar Products
  • 21
    • 84875477769 scopus 로고    scopus 로고
    • (accessed August 13, 2014)
    • Government of India, Department of Biotechnology, Ministry of Science and Technology, Central Drugs Standard Control Organization, Ministry of Health and Family Welfare: Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India. 2012. http://cdsco.nic.in/writereaddata/Bio%20Similar%20Guideline.pdf (accessed August 13, 2014).
    • (2012) Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India
  • 22
    • 84856779186 scopus 로고    scopus 로고
    • (accessed August 13, 2014)
    • Korean Food and Drug Administration: Guidelines on the Evaluation of Biosimilar Products. 2010. www.mfds.go.kr/jsp/common/download.jsp?fileinfo=S∗1∗%B5%BF%B5%EE%BB%FD%B9%B0%C0%C7%BE%E0%C7%B0%20% C6%F2%B0%A1%20%B0%A1%C0%CC%B5%E5%B6%F3%C0%CE%20(%BF%B5%B9%AE).pdf∗e9a03e5980ec4520b888e54dbf6ee908∗pdf∗/files/upload/1/TB-F-INFODATA/13325/e9a03e5980ec4520b888e54dbf6ee908∗265678∗2012:08:29%2016:10:23 (accessed August 13, 2014).
    • (2010) Guidelines on the Evaluation of Biosimilar Products
  • 24
    • 84928475369 scopus 로고    scopus 로고
    • Version 1.0, July (accessed August 13, 2014)
    • Therapeutic Goods Administration, Department of Health, Australian Government: Evaluation of Biosimilars. Version 1.0, July 2013. www.tga.gov.au/pdf/pm-argpm-biosimilars.pdf (accessed August 13, 2014).
    • (2013) Evaluation of Biosimilars
  • 25
    • 85082149622 scopus 로고    scopus 로고
    • (accessed August 13, 2014)
    • MEDSAFE New Zealand Medicines and Medical Devices Safety Authority: Medicines: Biosimilars. 2013. www.medsafe.govt.nz/profs/RIss/Biosimilars.asp (accessed August 13, 2014).
    • (2013) Medicines: Biosimilars
  • 29
    • 84926062530 scopus 로고    scopus 로고
    • [press release]. August 18, (accessed August 31, 2014)
    • Boehringer Ingelheim: FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (Insulin Glargine Injection) [press release]. August 18, 2014. http://us.boehringer-ingelheim.com/news-events/press-releases/press-release-archive/2014/08-18-14-fda-grants-tentativeapproval-lilly-boehringer-ingelheim-basaglar-insulin-glargineinjection.html (accessed August 31, 2014).
    • (2014) FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (Insulin Glargine Injection)
  • 30
    • 84873849289 scopus 로고    scopus 로고
    • Regulatory stratergies for biosimilars in regulated and emerging markets
    • Reddy S, Balamuralidhara V, Pramod Kumar TM, et al.: Regulatory stratergies for biosimilars in regulated and emerging markets. Pharma Times 2013;45:11-14.
    • (2013) Pharma Times , vol.45 , pp. 11-14
    • Reddy, S.1    Balamuralidhara, V.2    Pramod Kumar, T.M.3
  • 31
    • 84946604676 scopus 로고    scopus 로고
    • November 14, (accessed January 8, 2015)
    • GaBI Online: China Releases Draft Biosimilars Guidance. November 14, 2014. www.gabionline.net/Guidelines/Chinareleases-draft-biosimilars-guidance (accessed January 8, 2015).
    • (2014) China Releases Draft Biosimilars Guidance
  • 32
    • 21444442363 scopus 로고    scopus 로고
    • Biosimilar epoetins: An analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins
    • Combe C, Tredree RL, Schellekens H: Biosimilar epoetins: an analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005; 25:954-962.
    • (2005) Pharmacotherapy , vol.25 , pp. 954-962
    • Combe, C.1    Tredree, R.L.2    Schellekens, H.3
  • 36
    • 67549112400 scopus 로고    scopus 로고
    • Insights from the liraglutide clinical development program-The liraglutide effect and action in diabetes (LEAD) studies
    • McGill JB: Insights from the Liraglutide Clinical Development Program-the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgrad Med 2009;121: 16-25.
    • (2009) Postgrad Med , vol.121 , pp. 16-25
    • McGill, J.B.1
  • 37
    • 85082149613 scopus 로고    scopus 로고
    • Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 Amending, as Regards Pharmacovigilance, Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. (accessed August 13, 2014)
    • Official Journal of the European Union: Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 Amending, as Regards Pharmacovigilance, Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. 2010. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF (accessed August 13, 2014).
    • (2010) Official Journal of the European Union
  • 38
    • 80051570290 scopus 로고    scopus 로고
    • Biosimilar peptides: Need for pharmacovigilance
    • Joshi SR: Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India 2011;59(Suppl):44-47.
    • (2011) J Assoc Physicians India , vol.59 , pp. 44-47
    • Joshi, S.R.1
  • 39
    • 68649124703 scopus 로고    scopus 로고
    • Brussels: European Generic Medicines Association
    • European Generic Medicines Association: EGA Handbook on Biosimilar Medicines. Brussels: European Generic Medicines Association, 2008.
    • (2008) EGA Handbook on Biosimilar Medicines
  • 40
    • 79961107025 scopus 로고    scopus 로고
    • (accessed August 13, 2014)
    • U.S. Food and Drug Administration: Biologics Price Competition and Innovation (BPCI) Act. 2009. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ucm216146.pdf (accessed August 13, 2014).
    • (2009) Biologics Price Competition and Innovation (BPCI) Act
  • 44
    • 84946542353 scopus 로고    scopus 로고
    • (accessed August 13, 2014)
    • European Medicines Agency: Withdrawal Assessment Report for Insulin Human Rapid Marvel. 2008. www.ema.europa.eu/docs/en-GB/document-library/Application-withdrawal-assessment-report/2010/01/WC500067086.pdf (accessed August 13, 2014).
    • (2008) Withdrawal Assessment Report for Insulin Human Rapid Marvel
  • 45
    • 84946542353 scopus 로고    scopus 로고
    • (accessed August 13, 2014)
    • European Medicines Agency: Withdrawal Assessment Report for Insulin Human Long Marvel. 2008. www.ema.europa.eu/docs/en-GB/document-library/Application-withdrawal-assessment-report/2010/01/WC500067170.pdf (accessed August 13, 2014).
    • (2008) Withdrawal Assessment Report for Insulin Human Long Marvel
  • 46
    • 84946542353 scopus 로고    scopus 로고
    • (accessed August 13, 2014)
    • European Medicines Agency: Withdrawal Assessment Report for Insulin Human 30/70 Mix Marvel. 2008. www.ema.europa.eu/docs/en-GB/document-library/Application-withdrawal-assessment-report/2010/01/WC500067169.pdf (accessed August 13, 2014).
    • (2008) Withdrawal Assessment Report for Insulin Human 30/70 Mix Marvel
  • 48
    • 47549097069 scopus 로고    scopus 로고
    • Epoetinassociated pure red cell aplasia: Past, present, and future considerations
    • McKoy JM, Stonecash RE, Cournoyer D, et al.: Epoetinassociated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48:1754-1762.
    • (2008) Transfusion , vol.48 , pp. 1754-1762
    • McKoy, J.M.1    Stonecash, R.E.2    Cournoyer, D.3
  • 49
    • 69449095403 scopus 로고    scopus 로고
    • Biosimilar therapeutics-what do we need to consider?
    • Schellekens H: Biosimilar therapeutics-what do we need to consider? NDT Plus 2009;2(Suppl 1):i27-i36.
    • (2009) NDT Plus , vol.2 , pp. i27-i36
    • Schellekens, H.1
  • 50
    • 71649087076 scopus 로고    scopus 로고
    • Heterogeneity of commercial recombinant human growth hormone (r-hGH) preparations containing a thioether variant
    • Lispi M, Datola A, Bierau H, et al.: Heterogeneity of commercial recombinant human growth hormone (r-hGH) preparations containing a thioether variant. J Pharm Sci 2009;98:4511-4524.
    • (2009) J Pharm Sci , vol.98 , pp. 4511-4524
    • Lispi, M.1    Datola, A.2    Bierau, H.3
  • 51
    • 51249099154 scopus 로고    scopus 로고
    • The interpretation of glucose clamp studies of long-acting insulin analogues: From physiology to marketing and back
    • Swinnen SG, Holleman F, DeVries JH: The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 2008; 51:1790-1795.
    • (2008) Diabetologia , vol.51 , pp. 1790-1795
    • Swinnen, S.G.1    Holleman, F.2    DeVries, J.H.3
  • 52
    • 84928576980 scopus 로고    scopus 로고
    • Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T1DM: The ELEMENT 1 study
    • [abstract 69-OR]
    • Blevins T, Dahl D, Rosenstock J, et al.: Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T1DM: the ELEMENT 1 study [abstract 69-OR]. Diabetes 2014; 63(Suppl 1):A19.
    • (2014) Diabetes , vol.63 , pp. A19
    • Blevins, T.1    Dahl, D.2    Rosenstock, J.3
  • 53
    • 84928540283 scopus 로고    scopus 로고
    • Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T1DM or T2DM
    • [abstract 70-OR]
    • Deeg M, Ilag L, Huster WJ, et al.: Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T1DM or T2DM [abstract 70-OR]. Diabetes 2014;63(Suppl 1):A19.
    • (2014) Diabetes , vol.63 , pp. A19
    • Deeg, M.1    Ilag, L.2    Huster, W.J.3
  • 54
    • 84937813025 scopus 로고    scopus 로고
    • Comparative pharmacokinetics (PK) and pharmacodynamics (PD) of LY2963016 insulin glargine and EU- and U.S.-approved versions of Lantus® insulin glargine in healthy subjects
    • [abstract 889-P]
    • Linnebjerg H, Chen Quin Lam E, Seger ME, et al.: Comparative pharmacokinetics (PK) and pharmacodynamics (PD) of LY2963016 insulin glargine and EU- and U.S.-approved versions of Lantus® insulin glargine in healthy subjects [abstract 889-P]. Diabetes 2014;63(Suppl 1): A227.
    • (2014) Diabetes , vol.63 , pp. A227
    • Linnebjerg, H.1    Chen Quin-Lam, E.2    Seger, M.E.3
  • 55
    • 84928572271 scopus 로고    scopus 로고
    • Duration of action of 2 insulin glargine products, LY2963016 and Lantus®, in subjects with type 1 diabetes mellitus (T1DM)
    • [abstract 891-P]
    • Heise T, Zhang X, Chen Quin Lam E, et al.: Duration of action of 2 insulin glargine products, LY2963016 and Lantus®, in subjects with type 1 diabetes mellitus (T1DM) [abstract 891-P]. Diabetes 2014;63(Suppl 1):A228.
    • (2014) Diabetes , vol.63 , pp. A228
    • Heise, T.1    Zhang, X.2    Chen Quin-Lam, E.3
  • 56
    • 84928547217 scopus 로고    scopus 로고
    • Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T2DM: The ELEMENT 2 study
    • [abstract 64-OR]
    • Rosenstock J, Hollander P, Bhargava A, et al.: Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T2DM: the ELEMENT 2 study [abstract 64-OR]. Diabetes 2014;63(Suppl 1):A17.
    • (2014) Diabetes , vol.63 , pp. A17
    • Rosenstock, J.1    Hollander, P.2    Bhargava, A.3
  • 57
    • 84928559115 scopus 로고    scopus 로고
    • Comparative pharmacokinetics and pharmacodynamics of two insulin glargine products, LY2963016 and Lantus®, in healthy subjects at two dose levels
    • [abstract 890-P]
    • Zhang X, Chen Quin Lam E, Seger ME, et al.: Comparative pharmacokinetics and pharmacodynamics of two insulin glargine products, LY2963016 and Lantus®, in healthy subjects at two dose levels [abstract 890-P]. Diabetes 2014;63(Suppl 1):A227.
    • (2014) Diabetes , vol.63 , pp. A227
    • Zhang, X.1    Chen Quin-Lam, E.2    Seger, M.E.3
  • 58
    • 84872050633 scopus 로고    scopus 로고
    • Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A metaanalysis
    • Nanda KS, Cheifetz AS, Moss AC: Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a metaanalysis. Am J Gastroenterol 2013;108:40-47.
    • (2013) Am J Gastroenterol , vol.108 , pp. 40-47
    • Nanda, K.S.1    Cheifetz, A.S.2    Moss, A.C.3
  • 59
    • 53249142132 scopus 로고    scopus 로고
    • Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study
    • Drucker DJ, Buse JB, Taylor K, et al.: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-1250.
    • (2008) Lancet , vol.372 , pp. 1240-1250
    • Drucker, D.J.1    Buse, J.B.2    Taylor, K.3
  • 60
    • 84860250733 scopus 로고    scopus 로고
    • Clinical relevance of anti-exenatide antibodies: Safety, efficacy and cross-reactivity with long-term treatment
    • Fineman MS, Mace KF, Diamant M, et al.: Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012;14:546-554.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 546-554
    • Fineman, M.S.1    Mace, K.F.2    Diamant, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.